Skip to navigation Skip to content



Company Says MD1003 (high dose Biotin) Failed to Help Progressive MS in Phase 3 Trial

March 11, 2020

MedDay Pharmaceuticals announced that its second Phase 3 clinical trial of MD1003® (high-dose Biotin) in people with progressive MS failed to meet its primary or secondary endpoints. No adverse safety issues were reported.
  • The trial involved 642 people with primary progressive MS and secondary progressive MS who did not have recent relapses. Participants took MD1003 or placebo three times a day for 15 months.
  • The primary endpoint for the study was reversal of functional disability as measured by the proportion of participants with an improvement in either the standard EDSS scale (that largely tests walking ability), or in the time needed to walk 25 feet, at 12 months and confirmed at 15 months.
  • Biotin is considered a form of vitamin B, and is a component of enzymes in the body that help break down certain substances in the body. It was being tested to see if it could provide support for what may be increased energy demands of brain cells during the course of MS. Biotin is usually obtained from food.
  • The company announced plans to release more detailed results at an upcoming medical meeting.
 Read details about the trial on clinical
MD1003 is a registered trademark of MedDay Pharmaceuticals

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.